The Path of Least Resistance: Repositioned Drugs Surpass New Brands

October 24, 2012Media coverage

Article by PharmExec’s Clark Herman on the 505(b)(2) pathway for drug approval … Aris Persidis, president and co-founder of Biovista, a company focused on the 505(b)(2), adds, “In addition, the first to file patent regulations that will take effect in the US next year are making companies realize that they may be susceptible to competitors … Read More